To determine if the GPR4 antagonist had anti-SARS-CoV-2 effects when administered post-infection, we infected Vero E6 cells with virus for a 1-h adsorption period and then treated the cells with the GPR4 antagonist for 24 h (Figure 5B). This evidence concerns the gene GPR4 and infection.